176 related articles for article (PubMed ID: 33764159)
1. Treatment of a Hemophilia B Mouse Model with Platelet-Targeted Expression of Factor IX Padua.
Li B; Wu Z; Xu W; Han W; Liu J; Wang D; Zhang G
Hum Gene Ther; 2021 May; 32(9-10):506-516. PubMed ID: 33764159
[TBL] [Abstract][Full Text] [Related]
2. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.
Zhang G; Shi Q; Fahs SA; Kuether EL; Walsh CE; Montgomery RR
Blood; 2010 Aug; 116(8):1235-43. PubMed ID: 20445020
[TBL] [Abstract][Full Text] [Related]
3. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
[TBL] [Abstract][Full Text] [Related]
4. Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua.
Robinson MM; George LA; Carr ME; Samelson-Jones BJ; Arruda VR; Murphy JE; Rybin D; Rupon J; High KA; Tiefenbacher S
J Thromb Haemost; 2021 May; 19(5):1212-1218. PubMed ID: 33636038
[TBL] [Abstract][Full Text] [Related]
5. Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.
Wang D; Shao X; Wang Q; Pan X; Dai Y; Yao S; Yin T; Wang Z; Zhu J; Xi X; Chen Z; Chen S; Zhang G
Clin Transl Med; 2021 Mar; 11(3):e375. PubMed ID: 33783994
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Mediated In Situ Introduction or Integration of
Tang Q; Hu Z; Zhao J; Zhou T; Tang S; Wang P; Xiao R; Chen Y; Wu L; Zhou M; Liang D
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240366
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.
Kao CY; Yang SJ; Tao MH; Jeng YM; Yu IS; Lin SW
Thromb Haemost; 2013 Aug; 110(2):244-56. PubMed ID: 23676890
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
Nair N; De Wolf D; Nguyen PA; Pham QH; Samara-Kuko E; Landau J; Blouse GE; Chuah MK; VandenDriessche T
Blood; 2021 May; 137(21):2902-2906. PubMed ID: 33735915
[TBL] [Abstract][Full Text] [Related]
9. Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity.
Schroeder JA; Chen J; Chen Y; Cai Y; Yu H; Mattson JG; Monahan PE; Shi Q
Blood Adv; 2021 Mar; 5(5):1224-1238. PubMed ID: 33646304
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
[TBL] [Abstract][Full Text] [Related]
11. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
12. Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity.
Lombardi S; Aaen KH; Nilsen J; Ferrarese M; Gjølberg TT; Bernardi F; Pinotti M; Andersen JT; Branchini A
Br J Haematol; 2021 Jul; 194(2):453-462. PubMed ID: 34109608
[TBL] [Abstract][Full Text] [Related]
13. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.
Chen Y; Schroeder JA; Kuether EL; Zhang G; Shi Q
Mol Ther; 2014 Jan; 22(1):169-77. PubMed ID: 24042561
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of FXa-storing platelets in hemophilia B mice and the influence of alcohol on the platelets.
Han W; Huang R; Li B; Liu L; Xu W; Zhang G
Sci Rep; 2023 Oct; 13(1):16488. PubMed ID: 37779119
[TBL] [Abstract][Full Text] [Related]
15. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
Sekayan T; Simmons DH; von Drygalski A
Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.
Le Quellec S; Dane AP; Barbon E; Bordet JC; Mingozzi F; Dargaud Y; Marais T; Biferi MG; Négrier C; Nathawani AC; Enjolras N
Thromb Haemost; 2019 Dec; 119(12):1956-1967. PubMed ID: 31659733
[TBL] [Abstract][Full Text] [Related]
18. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
Samelson-Jones BJ; Finn JD; George LA; Camire RM; Arruda VR
JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219805
[TBL] [Abstract][Full Text] [Related]
19. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
20. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.
Cantore A; Nair N; Della Valle P; Di Matteo M; Màtrai J; Sanvito F; Brombin C; Di Serio C; D'Angelo A; Chuah M; Naldini L; Vandendriessche T
Blood; 2012 Nov; 120(23):4517-20. PubMed ID: 23043073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
